Adjuvant radiotherapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials

Wilfried Budach, Kai Kammers, Edwin Boelke, Christiane Matuschek, Wilfried Budach, Kai Kammers, Edwin Boelke, Christiane Matuschek

Abstract

Background: Radiotherapy (RT) improves overall survival (OS) of breast cancer patients after breast conserving surgery and after mastectomy in patients with involved lymph nodes (LN). The contribution of RT to the regional LN to this survival benefit was poorly understood. Recently, the results of three large randomized trials addressing this question have become available.

Material and methods: The published abstracts (full publication pending) of the MA.20 (n=1832) and the EORTC 22922-10925 (EORTC) (n=4004) trial and the full publication of the French trial (n=1334) were basis of the meta-analysis. Main eligibility criteria were positive axillary LN (all trials), LN negative disease with high risk for recurrence (MA.20), and medial/central tumor location (French, EORTC). The MA.20 and the EORTC trial tested the effect of additional regional RT to the internal mammary (IM) LN and medial supraclavicular (MS) LN, whereas in the French trial all patients received RT to the MS-LN and solely RT to the IM-LN was randomized. Primary endpoint was OS. Secondary endpoints were disease-free survival (DFS) and distant metastasis free survival (DMFS).

Results: Regional RT of the MS-LN and the IM-LN (MA.20 and EORTC) resulted in a significant improvement of OS (Hazard Ratio (HR) 0.85 (95% CL 0.75 - 0.96)). Adding the results of the French trial and using the random effects model to respect the different design of the French trial, the effect on OS of regional radiotherapy was still significant (HR 0.88 (95% CL 0.80 - 0.97)). The absolute benefits in OS were 1.6% in the MA.20 trial at 5 years, 1.6% in the EORTC trial at 10 years, and 3.3% in the French trial at 10 years (not significant in single trials). Regional radiotherapy of the MS-LN and the IM-LN (MA.20 and EORTC) was associated with a significant improvement of DFS (HR 0.85 (95% CL 0.77 - 0.94)) and DMFS (HR 0.82 (95% CL 0.73 - 0.92)). The effect sizes were not significantly different between trials for any end point.

Conclusion: Additional regional radiotherapy to the internal mammary and medial supraclavicular lymph nodes statistically significantly improves DFS, DMFS, and overall survival in stage I-III breast cancer.

Figures

Figure 1
Figure 1
Trial designs. Random = randomization. RT = radiotherapy. MS-LN-RT = radiotherapy of medial supraclavicular lymph nodes. MS-IM-RT = radiotherapy of medial supraclavicular and internal mammary lymph nodes.
Figure 2
Figure 2
Overall survival. The area of the symbols reflect the number of patients, MS + IM = medial supraclavicular and internal mammary lymph node irradiation, WBI/CWI = whole breast irradiation or chest wall irradiation, MS = medial supraclavicular lymph node irradiation.
Figure 3
Figure 3
Disease free survival. The area of the symbols reflect the number of patients. MS + IM = medial supraclavicular and internal mammary lymph node irradiation, WBI/CWI = whole breast irradiation or chest wall irradiation.
Figure 4
Figure 4
Distant metastasis free survival. The area of the symbols reflect the number of patients, MS + IM = medial supraclavicular and internal mammary lymph node irradiation, WBI/CWI = whole breast irradiation or chest wall irradiation.

References

    1. Darby S, McGale P, Correa C. et al.Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–1716.
    1. Sedlmayer F, Sautter-Bihl ML, Budach W. et al.DEGRO practical guidelines:radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer. Strahlenther Onkol. 2013;189:825–833. doi: 10.1007/s00066-013-0437-8.
    1. Clarke M, Collins R, Darby S. et al.Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–2106.
    1. Glechner A, Wockel A, Gartlehner G. et al.Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis. Eur J Cancer. 2013;49:812–825. doi: 10.1016/j.ejca.2012.09.010.
    1. Engel J, Emeny RT, Holzel D. Positive lymph nodes do not metastasize. Cancer Metastasis Rev. 2012;31:235–246. doi: 10.1007/s10555-011-9343-7.
    1. Veronesi U, Marubini E, Mariani L. et al.The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial. Eur J Cancer. 1999;35:1320–1325. doi: 10.1016/S0959-8049(99)00133-1.
    1. Arriagada R, Le MG, Mouriesse H. et al.Long-term effect of internal mammary chain treatment. Results of a multivariate analysis of 1195 patients with operable breast cancer and positive axillary nodes. Radiother Oncol. 1988;11:213–222. doi: 10.1016/0167-8140(88)90003-5.
    1. Grabenbauer GG. Internal mammary nodes in invasive breast carcinoma. To treat or not to treat? Strahlenther Onkol. 2004;180:690–694. doi: 10.1007/s00066-004-9193-0.
    1. Courdi A, Chamorey E, Ferrero JM, Hannoun-Levi JM. Influence of internal mammary node irradiation on long-term outcome and contralateral breast cancer incidence in node-negative breast cancer patients. Radiother Oncol. 2013.
    1. Stemmer SM, Rizel S, Hardan I. et al.The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: a prospective sequential nonrandomized study. J Clin Oncol. 2003;21:2713–2718. doi: 10.1200/JCO.2003.09.096.
    1. Olson RA, Woods R, Speers C. et al.Does the intent to irradiate the internal mammary nodes impact survival in women with breast cancer? a population-based analysis in British Columbia. Int J Radiat Oncol Biol Phys. 2012;83:e35–e41. doi: 10.1016/j.ijrobp.2011.11.066.
    1. Fowble B, Hanlon A, Freedman G. et al.Internal mammary node irradiation neither decreases distant metastases nor improves survival in stage I and II breast cancer. Int J Radiat Oncol Biol Phys. 2000;47:883–894. doi: 10.1016/S0360-3016(00)00526-5.
    1. Overgaard M, Jensen MB, Overgaard J. et al.Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641–1648. doi: 10.1016/S0140-6736(98)09201-0.
    1. Yates L, Kirby A, Crichton S. et al.Risk factors for regional nodal relapse in breast cancer patients with one to three positive axillary nodes. Int J Radiat Oncol Biol Phys. 2012;82:2093–2103. doi: 10.1016/j.ijrobp.2011.01.066.
    1. Hennequin C, Bossard N, Servagi-Vernat S. et al.Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys. 2013;86:860–866. doi: 10.1016/j.ijrobp.2013.03.021.
    1. Whelan TJOI, Ackerman I, Chapman JW, Chua B, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Craighead P, Nolan MC, Bowen J, McCready DR, Pritchard KI, Leine MN, Parulekar W, Parulekar W. NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. J Clin Oncol ASCO Annual Meeting Proceed (Post-Meeting Edition) 2011. p. 29.
    1. Poortmans PSH, Kirkove C, Budach V, Maingon P, Valli MC, Collette S, Fourquet A, Bartelink H, Van den Bogaert W. Irradiation of the internal mammary and medial supraclavicular lymph nodes in stage I to III breast cancer: 10 years results of the EORTC radiation oncology and breast cancer groups phase III trial 22922/10925. EJC. 2013;47(Suppl 2)
    1. Musat E, Poortmans P, Van den Bogaert W. et al.Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodes. Eur J Cancer. 2007;43:718–724. doi: 10.1016/j.ejca.2006.11.015.
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–2834. doi: 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>;2-8.
    1. Eubank WB, Mankoff DA, Takasugi J. et al.18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol. 2001;19:3516–3523.
    1. Lauber K, Ernst A, Orth M. et al.Dying cell clearance and its impact on the outcome of tumor radiotherapy. Front Oncol. 2012;2:116.
    1. Frey B, Rubner Y, Kulzer L, Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother. 2013.
    1. Viani GA, Afonso SL, Stefano EJ. et al.Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153. doi: 10.1186/1471-2407-7-153.
    1. Peto R, Davies C, Godwin J. et al.Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432–444.
    1. MacDonald SM, Jimenez R, Paetzold P. et al.Proton radiotherapy for chest wall and regional lymphatic radiation; dose comparisons and treatment delivery. Radiat Oncol. 2013;8:71. doi: 10.1186/1748-717X-8-71.
    1. Rudat V, Alaradi AA, Mohamed A. et al.Tangential beam IMRT versus tangential beam 3D-CRT of the chest wall in postmastectomy breast cancer patients: a dosimetric comparison. Radiat Oncol. 2011;6:26. doi: 10.1186/1748-717X-6-26.
    1. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005;6:557–565. doi: 10.1016/S1470-2045(05)70251-5.
    1. Mast ME, van Kempen-Harteveld L, Heijenbrok MW. et al.Left-sided breast cancer radiotherapy with and without breath-hold: does IMRT reduce the cardiac dose even further? Radiother Oncol. 2013;108(2):248–53. doi: 10.1016/j.radonc.2013.07.017.
    1. Matzinger O, Heimsoth I, Poortmans P. et al.Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925) Acta Oncol. 2010;49:24–34. doi: 10.3109/02841860903352959.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere